2021 m. gegužės 20 d., ketvirtadienis
18:00 – 20:00 val.
Treatment-resistant schizophrenia (TRS) is still underdiagnosed and TRS patients often get the right medication too late. Early identification of TRS has particular importance because it decreases the duration of inadequately controlled illness. Prompt and effective pharmacological intervention can change the course of the illness, significantly improving prognosis.
Clozapine is the only pharmacological treatment approved and recommended evidence-based treatment with clear established efficacy in TRS. Despite of guideline recommendations, clinical practice often show hesitation around early initiation of clozapine due to lack of knowledge and experience in clozapine management including its safety profile.
In this webinar, we are going to discuss TRS related guidelines vs real world clinical practices; the advantages of early clozapine initiation; and the routinely management of patients on clozapine including proactive side effect management.
If you have any questions, please contact Arvydas Beleckas at firstname.lastname@example.org.